Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose of RX-3117 in subjects
with advanced or metastatic solid tumors (Phase 1). The purpose of the Phase 2 portion is to
estimate anti-tumor activity in subjects with advanced malignancies (relapsed or refractory
pancreatic or advanced bladder cancer).